Table 3.
Target | Drug | Clinical trialb | Reference | |||||
---|---|---|---|---|---|---|---|---|
Target or mechanism type | Target or mechanism | Organsa | Drug Name | Mechanism | Class | Disease | Phase | Reference/Trial identifierc |
LOXd | LOXL2d | Liver, Kidney, Lung, Heart, Skin, Gut | β-aminopropionitrile (BAPN) | Inhibitor | Small molecule | Cardiac fibrosis | Preclinical | Martinez-Martinez et al., 2016 |
Simtuzumab (GS-6624) | Inhibitor | Monoclonal antibody | Liver fibrosis; IPFd | 2(completed); 2(terminated) | NCT01452308; NCT01769196 | |||
ROSd | NOX1d/NOX4 | Liver, Kidney, Lung, Heart, Pancreas, Skin | GM-CT-01 | Inhibitor | Polymer | Liver fibrosis | Preclinical | Traber and Zomer, 2013 |
GR-MD-02 | Inhibitor | Polymer | Liver fibrosis | 2(completed) | NCT02421094 | |||
GCS-100 | Inhibitor | Polymer | Renal fibrosis | 2(completed) | NCT01843790 | |||
ROS | GKT137831 | Inhibitor | Small molecule | Liver fibrosis | Preclinical | Aoyama et al., 2012 | ||
N-acetylcysteine* | Inhibitor | Small molecule | IPF | Approved| Preclinical | Demedts et al., 2005; Zhang et al., 2014 | |||
Mitoquinone | Inhibitor | Small molecule | Liver fibrosis | Preclinical | Vilaseca et al., 2017 | |||
Salvianolic acid B* | Inhibitor | Small molecule | Liver fibrosis; Renal fibrosis; IPF | Preclinical | Liu et al., 2002, 2016; Pan et al., 2011 | |||
Resveratrol* | Inhibitor | Small molecule | Liver fibrosis | 3(completed) | NCT02030977 | |||
Vitamin (mimic) | Liver, Kidney, Lung, Heart, Pancreas, Skin, Gut | Pyridoxamine | Inhibitor | Small molecule | Renal fibrosis | 2(completed) | NCT00320060 | |
α-tocopherol | Inhibitor | Small molecule | IPF | Approved| Preclinical | Deger et al., 2007 | |||
Collagen (mimic) | Liver, Kidney, Lung, Skin | IW001 | Inhibitor | Collagen | IPF | 1(completed) | NCT01199887 |
Drug belongs to monomer extracted from natural products.
Organs that had study report of corresponding targets in fibrosis treatment.
Clinical trial resource are from http://Clinicaltrials.gov.
Trial Identifier is the clinical trail identifier of corresponding drug.
LOX, lysyl oxidase; LOXL2, lysyl oxidase homolog 2; IPF, idiopathic pulmonary fibrosis; ROS, reactive oxygen species; NOX1, NADPH oxidase 1.